KAST Security Details
Share Structure
Market Value1 $13,125,254 a/o May 19, 2017
Authorized Shares 950,000,000 a/o Apr 19, 2017
Outstanding Shares 62,501,211 a/o Apr 19, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 269,544 a/o Jul 18, 2016
Kasten DAKOTA Life Sciences Receives CT State Funding Approval
PR Newswire
SIOUX FALLS, South Dakota, May 22, 2017
SIOUX FALLS, South Dakota, May 22, 2017 /PRNewswire/ --
Kasten Inc. (OTC Pink: KAST)
Kasten's DAKOTA Life Sciences has now received a letter of financial support approval from Commissioner Catherine H. Smith of the Connecticut Department of Economic Development (DECD). This support is comprised of an initial $100,000 Small Business Express Matching Grant and a Small Business Express Job Creation Incentive loan in the amount of up to $299,000.
"We are quite pleased to partner with the State of Connecticut and the City of Bridgeport," according to Steven Keough, the President of Kasten and Chief Operating Officer of DAKOTA Life Sciences. "We expect this initial collaboration will be expanded as our tempo increases" Keough added. The funds from the loan and grant will be utilized for machinery and equipment, as well as leasehold improvements at the Company's Bridgeport facility. Certain additional milestones must be met prior to accessing these DECD funds, and the Company is diligently advancing each of those milestones. The City of Bridgeport Office of Economic Development, headed by Mr. Thomas Gill, has been heavily involved in attracting high quality pharmaceutical and life sciences companies as part of a strategic economic growth plan for the area.
About Us: Kasten, Inc. (OTC Pink: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who cannot afford to miss a day of work, but whom are burdened by high risk of morbidity and healthcare costs.
Share Structure
Market Value1 $13,125,254 a/o May 19, 2017
Authorized Shares 950,000,000 a/o Apr 19, 2017
Outstanding Shares 62,501,211 a/o Apr 19, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 269,544 a/o Jul 18, 2016
Kasten DAKOTA Life Sciences Receives CT State Funding Approval
PR Newswire
SIOUX FALLS, South Dakota, May 22, 2017
SIOUX FALLS, South Dakota, May 22, 2017 /PRNewswire/ --
Kasten Inc. (OTC Pink: KAST)
Kasten's DAKOTA Life Sciences has now received a letter of financial support approval from Commissioner Catherine H. Smith of the Connecticut Department of Economic Development (DECD). This support is comprised of an initial $100,000 Small Business Express Matching Grant and a Small Business Express Job Creation Incentive loan in the amount of up to $299,000.
"We are quite pleased to partner with the State of Connecticut and the City of Bridgeport," according to Steven Keough, the President of Kasten and Chief Operating Officer of DAKOTA Life Sciences. "We expect this initial collaboration will be expanded as our tempo increases" Keough added. The funds from the loan and grant will be utilized for machinery and equipment, as well as leasehold improvements at the Company's Bridgeport facility. Certain additional milestones must be met prior to accessing these DECD funds, and the Company is diligently advancing each of those milestones. The City of Bridgeport Office of Economic Development, headed by Mr. Thomas Gill, has been heavily involved in attracting high quality pharmaceutical and life sciences companies as part of a strategic economic growth plan for the area.
About Us: Kasten, Inc. (OTC Pink: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceuticals designed to prevent and treat serious conditions arising both in hospital and community settings. We are principally focused on delivering solutions to those people who cannot afford to miss a day of work, but whom are burdened by high risk of morbidity and healthcare costs.
